Holen Sie sich die Stockscreener-App
3.285
10.11%
-0.385
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$3.67
Offen:
$3.63
24-Stunden-Volumen:
861.08K
Relative Volume:
0.35
Marktkapitalisierung:
$197.61M
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-102.44M
KGV:
-1.0806
EPS:
-3.04
Netto-Cashflow:
$-91.73M
1W Leistung:
+29.37%
1M Leistung:
-26.53%
6M Leistung:
-42.23%
1J Leistung:
-61.37%
1-Tages-Spanne:
$3.27
$3.63
1-Wochen-Bereich:
$2.5088
$3.7458
52-Wochen-Spanne:
$2.45
$10.99
Solid Biosciences Inc Stock (SLDB) Company Profile
Firmenname
Solid Biosciences Inc
Sektor
Branche
Telefon
617-337-4680
Adresse
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Vergleichen Sie SLDB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
3.285 | 197.61M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.57 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.38 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
613.00 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.01 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
245.56 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-13 | Eingeleitet | Wedbush | Outperform |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-15 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-06-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-03-28 | Eingeleitet | William Blair | Outperform |
| 2024-03-15 | Eingeleitet | Citigroup | Buy |
| 2024-03-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-05-27 | Eingeleitet | Jefferies | Buy |
| 2021-03-16 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-11 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-29 | Herabstufung | Citigroup | Neutral → Sell |
| 2019-08-19 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | Herabstufung | Goldman | Neutral → Sell |
| 2019-02-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-02-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | Eingeleitet | Citigroup | Sell |
| 2018-09-06 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
Certain Restricted Stock Units of Solid Biosciences Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Certain Common Stock of Solid Biosciences Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Solid Biosciences stock hits 52-week low at $2.47 By Investing.com - Investing.com South Africa
Solid Biosciences stock hits 52-week low at $2.47 - Investing.com Australia
Can Solid Biosciences Challenge Sarepta in the DMD Market? - MSN
Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space - Seeking Alpha
Can Solid Biosciences Challenge Sarepta In The DMD Market? - Barchart.com
Solid Biosciences stock hits 52-week low at $2.88 - Investing.com Australia
Solid Biosciences stock hits 52-week low at $2.88 By Investing.com - Investing.com South Africa
Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewswire
Exclusive Access: Solid Biosciences Leadership Team Headlines Two Major Healthcare Conferences - Stock Titan
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Solid Biosciences reports inducement grants under Nasdaq listing rule - TipRanks
Solid Biosciences Expands Team with 43,374 RSU Grants in Strategic Hiring Move - Stock Titan
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
Truist Financial Keeps Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
Solid Biosciences Inc.'s (NASDAQ:SLDB) market cap dropped US$53m last week; Private equity firms bore the brunt - simplywall.st
Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha
Solid Biosciences Inc. (SLDB): Among Top Insider Purchases Last Month - Insider Monkey
Solid Biosciences director Kahn Clare buys $9,924 in stock - Investing.com India
Solid Biosciences director Kahn Clare buys $9,924 in stock By Investing.com - Investing.com Australia
Solid Biosciences’ SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia
Solid Biosciences’ SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com South Africa
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Solid Biosciences Inc. (NASDAQ:SLDB) Short Interest Update - Defense World
Q1 EPS Forecast for Solid Biosciences Boosted by Analyst - Defense World
Top 10 Insider Purchases Last Month - Insider Monkey
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - GlobeNewswire
Solid Biosciences Inc. to Present Phase 1/2 INSPIRE DUCHENNE Trial Data on SGT-003 Gene Therapy for Duchenne Muscular Dystrophy at 2025 MDA Conference - Nasdaq
Breakthrough DMD Gene Therapy Results: Solid Bio Reveals INSPIRE Trial Data at Major Conference - StockTitan
SLDBSolid Bioscience Latest Stock News & Market Updates - Stock Titan
Solid Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Solid Biosciences Inc. (NASDAQ:SLDB) Shares Acquired by Rhumbline Advisers - Defense World
HC Wainwright Issues Positive Forecast for Solid Biosciences (NASDAQ:SLDB) Stock Price - Defense World
Solid Biosciences shares leap on raised price target to $20 By Investing.com - Investing.com Canada
Solid Biosciences price target raised to $20 from $16 at H.C. Wainwright - TipRanks
FY2026 Earnings Forecast for SLDB Issued By William Blair - Defense World
Chardan Capital Reaffirms “Buy” Rating for Solid Biosciences (NASDAQ:SLDB) - Defense World
SLDB Stock Rallies 60% in a Month: Here's What You Should Know - MSN
Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade - Yahoo Finance
Solid Biosciences Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
Solid Biosciences stock target holds at $15 on therapy optimism - Investing.com
Solid Biosciences: Promising Gene Therapy Advancements and Strategic Pipeline Expansion Justify Buy Rating - TipRanks
Solid Biosciences: Positive DMD Program Developments and Strong Financial Position Justify Buy Rating - TipRanks
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
Finanzdaten der Solid Biosciences Inc-Aktie (SLDB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Solid Biosciences Inc-Aktie (SLDB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Inv | 10% Owner |
Feb 19 '25 |
Buy |
4.03 |
1,000,000 |
4,030,000 |
5,034,582 |
| PERCEPTIVE ADVISORS LLC | Director |
Feb 19 '25 |
Buy |
4.03 |
5,000,000 |
20,150,000 |
11,833,539 |
| Adage Capital Management, L.P. | 10% Owner |
Feb 18 '25 |
Buy |
7.56 |
252,545 |
1,909,240 |
4,248,084 |
| Hanrahan Jessie | Chief Regulatory Officer |
Feb 14 '25 |
Sale |
3.96 |
3,079 |
12,193 |
19,281 |
| Brooks Gabriel | Chief Medical Officer |
Feb 14 '25 |
Sale |
3.96 |
3,256 |
12,894 |
22,812 |
| Tan Kevin | CFO & Treasurer |
Feb 14 '25 |
Sale |
3.96 |
3,164 |
12,529 |
32,250 |
| Howton David T | Chief Operating Officer |
Feb 14 '25 |
Sale |
3.96 |
5,561 |
22,022 |
24,789 |
| Herzich Paul | Chief Technology Officer |
Feb 14 '25 |
Sale |
3.96 |
2,688 |
10,644 |
18,388 |
| Cumbo Alexander | President and CEO |
Feb 14 '25 |
Sale |
3.96 |
11,365 |
45,005 |
60,717 |
| Ganot Ilan | Director |
Feb 14 '25 |
Sale |
3.96 |
1,711 |
6,776 |
14,839 |
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):